))
Columvi, Linzess, Recell, Bylvay, Eroxon
Manage episode 407556919 series 3561458
Content provided by Emma Nichols, PhD and Emma Hitt Nichols. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Emma Nichols, PhD and Emma Hitt Nichols or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Get our free download! Implementing AMA Style – 8 Things to Get Right
In this episode, we discuss the latest FDA approvals from June 12 – June 16, 2023. Here are the key highlights:
· The FDA has granted accelerated approval to Roche's Columvi® (glofitamab) for the treatment of DLBCL and large B-cell lymphoma.
· Linzess® (linaclotide) capsules have been approved by the FDA to treat functional constipation in pediatric patients aged 6 to 17 years.
· The FDA has granted premarket approval to the RECELL® autologous cell harvesting device for the treatment of vitiligo, a skin condition characterized by depigmentation.
· Bylvay® (odevixibat) has received FDA approval for the treatment of cholestatic pruritus in patients with Alagille syndrome.
· The FDA has approved Eroxon®, a topical gel, as an over-the-counter treatment for erectile dysfunction.
If you need medical writing assistance please visit Nascent Medical. Nascent Medical specialize in high-quality medical writing services and they are available on call to meet your deadlines. Nascentmc.com
Intro and outro music
49 episoade
Distribuie
